Table 1.
Patient characteristics at diagnosis.
| Age at diagnosis | Number of Patients | Percent | |
|---|---|---|---|
| Mean (range) | 68.2 | ||
| Median | 68.6 (43.8–89.2) | ||
| 40–49 | 4 | 0.8 | |
| 50–59 | 72 | 15.1 | |
| 60–69 | 190 | 39.8 | |
| 70–79 | 180 | 37.7 | |
| 80–89 | 31 | 6.5 | |
| PSA level at treatment | (ng/mL) | ||
| Combined mean (range) | 6 | ||
| Median | 5.3 (0.1–19) | ||
| PSA level at diagnosis | Number of patients | Percent | p-Value |
| <4 ng/mL | 79 | 16.6 | 0.08 |
| 4–10 ng/mL | 353 | 74.0 | |
| >10–20 ng/mL | 45 | 9.4 | |
| Risk Category | |||
| Low | 324 | 67.9 | 0.015 |
| Intermediate | 153 | 32.1 | |
| Clinical Stage | |||
| T1a | 2 | 0.4 | <0.001 |
| T1c | 434 | 91 | |
| T2a | 41 | 8.6 | |
| Gleason Score | |||
| 6 | 354 | 74.2 | 0.008 |
| 7 (3 + 4) | 83 | 17.4 | |
| 7 (4 + 3) | 40 | 8.4 | |
| Hormone Treatment | |||
| No | 426 | 89.3 | 0.31 |
| Yes | 51 | 10.7 | |
| RT Treatment | |||
| 35 Gy | 154 | 32.3 | 0.098 |
| 36.25 Gy | 323 | 67.7 | |